<DOC>
	<DOCNO>NCT03018054</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multi-center study evaluate efficacy safety E6007 daily 8 week Japanese participant moderate active ulcerative colitis . Participants stratify prior therapeutic treatment Mayo score Baseline , randomize 1:1:1 receive E6007 30 milligram ( mg ) , E6007 60 mg placebo .</brief_summary>
	<brief_title>Study E6007 Japanese Patients With Moderate Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Japanese participant age 20 74 year time inform consent Participants diagnosis base Revised Diagnostic Criteria Ulcerative Colitis ( UC ) issue Research Group Intractable Inflammatory Bowel Disease Designated Specified Disease Ministry Health , Labor Welfare Japan ( 2013 ) least 4 week start administration study drug Active UC participant determine Baseline complete Mayo score 6 10 point endoscopic subscore ≥2 rectal bleeding subscore ≥1 Participants currently treat oral 5ASA immunomodulator corticosteroid inadequate response intolerance , corticosteroid dependent Participants see outpatient basis Has voluntarily consent , write , participate study able willing comply requirement study protocol Reduction partial Mayo score ≥3 point Baseline Screening Diagnosed rightsided segmental colitis , proctitis Baseline endoscopy Received antitumor necrosis factor ( TNF ) agent 2 year , within 12 week prior Baseline History colectomy , plan surgery treatment UC Screening Baseline White blood cell count 3000/microliters ( µL ) Screening History suspect history central nervous system disorder find Screening Baseline Current complication suspect malignancy toxic megacolon Screening Baseline Prior history current complication colonic dysplasia Screening Baseline History severe drug allergy Screening Baseline Received live vaccine within 4 week prior Baseline QTc repeatedly 450 millisecond ( m ) electrocardiogram ( ECG ) test Screening In case woman : nursing mother pregnant woman Screening Baseline Refusal use medically suitable contraception ( participant participant 's partner ) throughout entire study period , participant man capable reproduction woman childbearing potential Female participant want become pregnant male participant whose partner want become pregnant throughout entire study period Evidence clinically significant disease opinion investigator ( ) could affect participant 's safety interfere study assessment Screening Baseline History medical condition concomitant medical condition opinion investigator ( ) would compromise participant 's ability safely complete study Screening Baseline A positive finding human immunodeficiency virus antigen antibody test Screening In test conduct Screening , positive finding following : hepatitis B virus surface antigen , hepatitis B virus surface antibody , hepatitis B virus core antibody , hepatitis C virus antibody Any result negative tuberculosis test Screening Findings indicate history tuberculosis chest Xray Screening History drug alcohol dependency abuse within approximately last 2 year prior Screening Baseline Use illegal recreational drug Screening Baseline Currently enrol another clinical trial use investigational drug device within 16 week precede informed consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>moderate active ulcerative colitis</keyword>
	<keyword>Japanese</keyword>
</DOC>